Eli Lilly Corp. diskutieren

Eli Lilly and Company (NYSE: LLY) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $885.00 price target on the stock.

Eli Lilly and Company (NYSE: LLY) had its "buy" rating re-affirmed by analysts at Deutsche Bank Aktiengesellschaft. They now have a $1,025.00 price target on the stock.

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at Truist Financial Co. from $1,000.00 to $1,033.00. They now have a "buy" rating on the stock.

Eli Lilly and Company (NYSE: LLY) is now covered by analysts at Sanford C. Bernstein. They set an "outperform" rating and a $1,100.00 price target on the stock.

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at Citigroup Inc. from $1,060.00 to $1,250.00. They now have a "buy" rating on the stock.

Eli Lilly and Company (NYSE: LLY) had its price target lowered by analysts at Bank of America Co. from $1,150.00 to $1,100.00. They now have a "buy" rating on the stock.

Eli Lilly and Company (NYSE: LLY) had its price target lowered by analysts at Barclays PLC from $1,025.00 to $975.00. They now have an "overweight" rating on the stock.

Eli Lilly and Company (NYSE: LLY) had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $1,025.00 to $1,015.00. They now have a "buy" rating on the stock.

Eli Lilly and Company (NYSE: LLY) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $1,000.00 price target on the stock.

Hey there, fellow investor! I've been digging into Eli Lilly, and boy, do they have some exciting things cooking! Their GLP-1 drugs Zepbound and Mounjaro are making waves in the obesity treatment market. It's like they've found the golden ticket in the pharma world! The White House is even talking about expanding Medicare and Medicaid coverage for these drugs, which could be a game-changer for Lilly's bottom line. Sure, there's some uncertainty with the FDA's decision on shortages, but that's just keeping things interesting, right? The recent dip in price feels like a sale at your favorite store - a chance to grab a piece of this innovative company at a discount. With their strong pipeline and growing market for obesity drugs, I think Lilly's got room to run. It's not all smooth sailing, but hey, where's the fun in that? I'm seeing potential for growth here, so I'm leaning towards a buy. Just remember, the pharma market can be as unpredictable as a rollercoaster, so buckle up and enjoy the ride!

Eli Lilly and Company (NYSE: LLY) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.

Hey there! Let's talk Eli Lilly, shall we? This pharma giant's stock is looking pretty spicy right now at $758.8. I've been digging into the news, and it seems like the healthcare sector's been taking a bit of a beating lately. But you know what? I think Eli Lilly might just be the diamond in the rough. Sure, there's some drama with those PBM companies and potential reforms, but Lilly's got some aces up its sleeve. They're like the cool kid at school who always has the latest gadget - constantly innovating and pushing boundaries in the drug world. With their strong pipeline and focus on areas like diabetes and obesity, I've got a hunch they'll weather the storm better than most. It's not all sunshine and rainbows, mind you - the healthcare sector's facing some headwinds. But if Lilly plays its cards right, I reckon we could see it hit the $800 mark. It's a bit of a rollercoaster ride, but isn't that what makes the stock market fun? Just remember, I'm not a fortune teller - this is just my two cents based on what I've seen!

Eli Lilly and Company (NYSE: LLY) had its price target lowered by analysts at Citigroup Inc. from $1,250.00 to $1,190.00. They now have a "buy" rating on the stock.

Eli Lilly and Company (NYSE: LLY) had its price target lowered by analysts at Wells Fargo & Company from $1,000.00 to $970.00. They now have an "overweight" rating on the stock.

Eli Lilly's looking pretty sweet right now, folks! Their weight loss drugs are making waves, and they're not slowing down. Sure, the stock's had a wild ride lately, but isn't that just part of the thrill? With their strong pipeline and focus on innovation, Lilly's like a rollercoaster that's just hit the top of the hill - ready for an exhilarating run. Their CEO hasn't bought company shares in years, which might raise an eyebrow, but he's still 'money good' according to Jim Cramer. And speaking of Cramer, he's all about those prescription numbers for Lilly's drugs. It's not just about the pill, it's about how many people are lining up for it. With scripts on the rise and potential breakthroughs in AI-driven healthcare, Lilly could be cooking up something big. The recent dip? Think of it as a sale on a premium stock. There's still some uncertainty around supply and competition, but Lilly's got the secret sauce that could keep them ahead of the pack. It's a bit pricey compared to some, but sometimes you've got to pay up for quality, right? Just remember, the pharma world can change faster than you can say 'side effects may include...', so keep your eyes peeled!

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at Truist Financial Co. from $1,029.00 to $1,038.00. They now have a "buy" rating on the stock.

Hey there! I've been keeping an eye on Eli Lilly, and I've gotta say, I'm pretty impressed. Their recent expansion into cutting-edge cancer therapies with AdvanCell is super exciting. Plus, their Q4 results were off the charts - we're talking 45% revenue growth! The success of their GLP-1 drugs like Mounjaro is really driving things. Sure, the stock's pricey, but with their pipeline and growth trajectory, I think there's still room to run. It's like they've found the golden ticket in pharma. The dividend growth is nice too, even if the yield is low. Not without risks, but I'm bullish overall. This could be the 'Apple of pharma' in the making!

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at Wells Fargo & Company from $970.00 to $1,100.00. They now have an "overweight" rating on the stock.

Eli Lilly and Company (NYSE: LLY) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $888.00 price target on the stock, down previously from $892.00.

Eli Lilly and Company (NYSE: LLY) had its price target lowered by analysts at Morgan Stanley from $1,146.00 to $1,124.00. They now have an "overweight" rating on the stock.